Sexual functioning post-myocardial infarction: effects of beta-blockers, psychological status and safety information

M C Rosal1, J Downing, A B Littman

  • 1Behavioral Medicine Unit (Department of Psychiatry), Massachusetts General Hospital/Harvard Medical School.

Insights

Psychological distress, not beta-blockers or safety information, significantly impacts sexual function in myocardial infarction (MI) survivors. Addressing mental health is crucial for improving quality of life post-MI.

Area of Science:

  • Cardiology
  • Psychology
  • Sexual Health

Background:

  • Sexual dysfunction affects a significant portion (34-75%) of patients following myocardial infarction (MI).
  • This can severely limit their quality of life and overall well-being.
  • Understanding contributing factors is essential for effective patient care.

Purpose of the Study:

  • To investigate the impact of beta-blocker use, psychological distress, and information on sexual activity safety on sexual functioning in male post-MI patients.
  • To identify key predictors of decreased sexual activity after myocardial infarction.

Main Methods:

  • A study involving 63 male post-MI patients and their spouses, post-cardiac rehabilitation.
  • Partial variance analyses were used to assess the unique contribution of each factor.
  • Statistical controls for patient age were applied.

Main Results:

  • Psychological distress was a significant predictor, uniquely explaining 24% of the variance in decreased sexual activity (p < 0.002).
  • Beta-blocker intake did not significantly predict changes in sexual functioning.
  • Information received regarding the safety of sexual activity was also not a significant predictor.

Conclusions:

  • Psychological distress is a primary factor influencing sexual dysfunction in post-MI patients.
  • Current interventions may need to focus more on psychological support rather than solely on medication or safety information.
  • Interdisciplinary approaches integrating psychological assessment and intervention are recommended for improved outcomes.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...